Oncolytics Biotech Files 6-K for February 2025

Ticker: ONCY · Form: 6-K · Filed: Feb 10, 2025 · CIK: 1129928

Oncolytics Biotech INC 6-K Filing Summary
FieldDetail
CompanyOncolytics Biotech INC (ONCY)
Form Type6-K
Filed DateFeb 10, 2025
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, foreign-private-issuer, sec-filing

Related Tickers: ONC

TL;DR

ONCOLYTICS BIOTECH (ONC) filed a 6-K for Feb 2025, confirming foreign private issuer status and 20-F annual report filings.

AI Summary

Oncolytics Biotech Inc. filed a Form 6-K on February 10, 2025, reporting for the month of February 2025. The company is a foreign private issuer based in Calgary, Alberta, Canada, and is subject to the 1934 Securities Exchange Act. They are filing as a public document and will file annual reports under Form 20-F.

Why It Matters

This filing indicates ongoing reporting requirements for Oncolytics Biotech Inc. as a foreign private issuer, providing transparency to investors about their regulatory status.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new financial or operational information that would inherently increase risk.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The Form 6-K is a report of a foreign private issuer filed for the month of February 2025, providing information to the SEC.

What is the filing date of this document?

This Form 6-K was filed on February 10, 2025.

Where is Oncolytics Biotech Inc. headquartered?

Oncolytics Biotech Inc. is located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada.

Under which form will Oncolytics Biotech Inc. file its annual reports?

Oncolytics Biotech Inc. indicates it files annual reports under Form 20-F.

Is Oncolytics Biotech Inc. submitting this Form 6-K in paper format?

The filing does not indicate that the Form 6-K is being submitted in paper format under Regulation S-T Rule 101(b)(1).

Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2025-02-10 08:51:33

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date February 7, 2025 Kirk Look Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing